Based in Vero Beach, Florida, Quinton Oswald previously guided Notal Vision, an early commercial stage firm focused on age-related macular degeneration (AMD), as CEO. Presently holding board and advisor-to-CEO responsibilities, Quinton Oswald is working toward a national rollout of an innovative Notal product pipeline.

Mr. Oswald’s position builds on an extensive track record of ophthalmology drug and device development innovation that includes the launch of Lucentis, a pioneering drug for treating wet AMD, while at Genentech, Inc. From 2010 to 2013, he served as CEO of SARcode Corporation, where he oversaw all phases of developing the dry eye medication Xiidra. He raised $45 million in support of phase 2 and 3 programs, and oversaw successful FDA negotiations for the pivotal phase 3 trial. This ultimately resulted in the acquisition of SARcode Bioscience by Shire. He was retained to expand the firm’s ophthalmology business and bring the lead candidate to market.

Mr. Oswald maintains an active industry presence and reviews presentations at the Ophthalmology Innovation Summit. Originally from South Africa, he has global leadership experience in a number of developing countries, as well as the United States and Europe.